Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Q2 Revenues Up, Income Down; Signs Supply Agreement with Novartis

NEW YORK, Aug 3 (GenomeWeb News) - Qiagen Monday reported a 14 percent year-over-year increase in second quarter revenues, amid decreased net income.

 

The Venlo, Netherlands life sciences tools company had $98.6 million in revenues, compared to $86.3 million in the same period of last year. Net income totaled $8.8 million, versus $11.1 million in the second quarter of 2003.

 

Separately, Qiagen announced that it has signed a supply agreement with Novartis for consumables related to nucleic acid stabilization, separation, purification and handling, as well as siRNA and instrumentation. The companies did not disclose the financial terms of the agreement.

 

Qiagen said the expenses for the second quarter included relocation and restructuring, as well as charges related to the buyout of the company's synthetic DNA business unit during the quarter.

 

R&D expenses increased to $9.3 million, compared to $7.6 million in Q2 2003.

 

As of June 30, the company had $149.6 million in cash, cash equivalents, and marketable securities, compared to $105.5 million as of December 31, 2003.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more